Robotic-Assisted Vitreoretinal Surgery

From EyeWiki

All content on Eyewiki is protected by copyright law and the Terms of Service. This content may not be reproduced, copied, or put into any artificial intelligence program, including large language and generative AI models, without permission from the Academy.


Surgical Therapy

Robotic-assisted vitreoretinal surgery (RAVS) offers a transformative approach to managing complex retinal conditions by enhancing surgical precision, reducing physiological tremor, and enabling micrometer-scale maneuvers beyond the capabilities of the human hand.[1] [2] Systems such as the Preceyes Robotic Surgical System—which has received CE marking—have demonstrated success in performing delicate tasks like internal limiting membrane (ILM) peeling, subretinal injections, and retinal vein cannulation, which are critical for the delivery of gene therapy and stem cell-based treatments. [3][4] [5]

These systems utilize motion scaling, tremor filtering, and virtual z-boundaries to minimize iatrogenic trauma and enhance instrument control in the subretinal space.[6][4] Recent advances now incorporate artificial intelligence-assisted guidance and semi-automated control mechanisms, allowing for partial automation of tasks such as subretinal injections with high first-attempt success rates (up to ~91.7% ), representing a shift from purely assistive to semi-autonomous systems. This study involved 48 rabbits, and although promising, these results have not yet established clinical superiority in human patients[7][8]

Recent randomized controlled simulator studies have shown that robotic assistance significantly improves surgical precision and reduces retinal tissue damage, especially in novice surgeons, though at the cost of increased operative time.[4] However, operative times may decrease with experience and workflow optimization, narrowing the gap with manual surgery, although they generally remain longer.[9][10]

Despite these advancements, current limitations include high cost, limited accessibility, and the need for specialized training. [11][12] Additional limitations include increased initial cognitive load due to integration of advanced imaging such as intraoperative optical coherence tomography (OCT), although this may improve depth perception and surgical accuracy over time. [13]

Future directions focus on integrating real-time force feedback, artificial intelligence, and intraoperative optical coherence tomography (OCT) to further refine robot-assisted performance and expand its adoption in clinical practice. [14][15] A 2024 systematic review of clinical studies found no difference in ocular harms between robot-assisted and conventional eye surgery, and no consistent advantage in effectiveness or practicality, which reflects the early stage of clinical translation rather than a negative result.[16]

Background/Historical Overview

The evolution of RAVS spans over five decades and reflects broader technological advancements in precision medicine. Initial progress in ophthalmic robotics began with Robert Machemer’s introduction of the handheld motorized vitrectomy cutter in the 1970s, a tool that revolutionized the management of posterior segment diseases by enabling safe and controlled removal of the vitreous. [17] This was followed in the 1980s by the development of early ocular micromanipulators by Spitznas and later Guerrouad and Vidal, setting the stage for more complex microsurgical instrumentation. [18][19]

The broader field of robotic surgery underwent significant transformation during the 1980s and 1990s, with platforms like PUMA 200 and RoboDoc used for neurosurgery and orthopedics, respectively. [20] [21] However, it wasn't until 2007 that robotic systems entered ophthalmology, when the da Vinci Surgical System was used to repair corneal lacerations in porcine eyes using 10-0 nylon sutures.[22] Despite its precision, the da Vinci system’s 1-mm resolution proved inadequate for retinal surgery, which often requires micron-scale precision. [23]

This precision gap drove the development of specialized robotic systems for vitreoretinal surgery, where the high sensitivity of retinal tissue demands ultra-fine control.[24][5] More recently, emerging platforms have expanded beyond traditional telemanipulation to include head-mounted and compact robotic systems designed to stabilize both the surgical instrument and the patient’s eye in real time, compensating for physiologic motion such as respiration and heartbeat. These systems function by passively reducing relative motion between the robot and the eye through head-mounted stabilization, enabling submicron-scale precision and significantly improved success rates in subretinal injection tasks compared to manual techniques. [25][26]

Since then, numerous robotic platforms have been developed, the majority still in preclinical stages. While most systems remain investigational, the field is transitioning from proof-of-concept to early clinical translation, with multiple platforms undergoing human trials and validation studies.[27] Notably, several robotic systems have been tested in humans: the Preceyes Surgical System, the KU Leuven co-manipulator, the Luca robotic program, and the Mynutia comanipulation system, which has recently completed in-human feasibility studies. [28] [29][30] Preceyes, developed in the Netherlands, became the first system to receive CE marking in 2019 and remains the most widely studied.[28][31]

A complementary way to classify these platforms, which accommodates the newer systems, divides them into operation systems that manipulate tissue, operation-assistance systems that suppress tremor while the surgeon retains direct control, and observation systems that hold and position endoscopes or illumination.[2]

Modern Pre-clinical vitreoretinal robotic systems fall into three main categories:

  1. Handheld tools like the Micron, developed through collaboration between Carnegie Mellon and Johns Hopkins, are designed to cancel physiological tremor. Micron has demonstrated attenuation of hand motion by at least 15 decibels, a fivefold reduction, with position error reduced by 32 to 52 percent and significantly improved success rates for retinal vein cannulation in porcine models. [32][33]
  2. Co-manipulation platforms such as the Steady-Hand Eye Robot, also from Johns Hopkins, utilize force-sensing technology to smooth manual tool movements and reduce tremor without removing surgeon control. [34][35]
  3. Telemanipulator systems like the Preceyes Surgical System and IRISS (developed at UCLA) use master-slave configurations, motion scaling, and advanced imaging. IRISS is designed for both anterior and posterior segment surgeries and allows surgeons to operate from a remote console with 3D visualization and real-time joystick input. [36][12][37]
  4. Semi-autonomous robotic systems (emerging category), such as HiPOSuR, incorporate automated or partially automated execution of specific surgical steps, particularly subretinal injections, improving consistency and success rates.[8]

Work using the IRISS console has since characterized how control mode and motion scaling affect performance, finding that a control mode emulating manipulation at the instrument tip outperformed proximal control, and that higher scaling factors reduced trajectory error and simulated tissue damage.[38]

Other innovative platforms include the RAMSIS system from the Technical University of Munich, which employs hybrid actuation with piezoelectric motors and has shown success in subretinal depth tracking in pig eyes using OCT guidance. [39][40][41] Additionally, OctoMag, a magnetically controlled system, enables intraocular manipulation of microrobots without tethers. Though promising for subretinal injections and vein cannulation, OctoMag systems currently face challenges with alignment precision and angular control. [42][43]

In clinical application at least four robotic systems have now been tested in humans. Two are telemanipulators, in which the surgeon drives the instruments from a separate controller, and two are co-manipulators, in which the surgeon and robot hold the same instrument. In all four, every instrument movement is initiated and controlled by the surgeon; none has performed a surgical step autonomously in patients.

  • Preceyes Surgical System: Developed at Eindhoven University of Technology and commercialized by Preceyes BV (the Netherlands), this is a single-arm telemanipulator: a compact instrument manipulator mounted at the head of the operating table holds one standard vitreoretinal instrument, while the surgeon, seated at the operating microscope, drives it with a handheld motion controller. The system scales down and filters the surgeon’s hand movements to achieve approximately 10 µm tool-tip precision, adds virtual safety boundaries, a position-hold function, and intraoperative OCT integration, and in 2019 became the first vitreoretinal robot to receive CE marking. In the first-in-human randomized trial in Oxford, 12 patients requiring ERM or ILM peeling were assigned to robot-assisted or manual surgery under general anesthesia; robotic membrane dissection was successful in both groups, with no statistically significant difference in retinal microtrauma. However, robotic membrane dissection required significantly longer (median 4 min 55 s vs. 1 min 20 s). A follow-up randomized trial in 12 patients with submacular hemorrhage from neovascular age-related macular degeneration used the robot to advance and hold a 41G cannula in the subretinal space while up to 100 µL of tPA was injected by foot pedal under local anesthesia, with operative time, retinal microtrauma, hemorrhage displacement, and visual gains comparable to manual surgery. No step was automated, as the robot executed only the surgeon’s scaled and filtered movements; the overall takeaway was that robot-assisted membrane peeling and subretinal delivery are feasible in patients, providing a platform for future gene and cell therapy delivery.[31][44][45] [46][47]
  • KU Leuven co-manipulator: Rather than being steered from a console, this system uses co-manipulation: the surgeon, operating at the microscope as in conventional surgery, holds the instrument directly while a single compact robotic arm attached to the operating table’s head support holds it at the same time, with no joystick or remote controls. A four-degree-of-freedom remote-center-of-motion mechanism keeps the instrument pivoting at the scleral port to stabilize the eye, speed-dependent motion-opposing forces damp hand tremor, and releasing a foot pedal locks the instrument in place within 30 ms to an accuracy of about 10 µm. In a phase 1 trial at University Hospitals Leuven beginning in January 2017, four patients with central retinal vein occlusion underwent vitrectomy followed by robot-assisted cannulation of a retinal vein approximately 100–150 µm in diameter with a 30 µm glass micropipette, and ocriplasmin was infused into the vein for up to 10 minutes. No step was automated, but the locked robot held the needle motionless inside the vein for the entire infusion, a task beyond the stability of the unaided hand. This was the first robot-assisted retinal vein cannulation in humans and established the technique’s technical feasibility, although the small study was insufficient to definitively establish procedural safety or clinical efficacy. [48][49][50][51]
  • Mynutia comanipulation system: Mynutia, a spin-off of the KU Leuven surgical robotics group, is the commercial successor of this co-manipulator and keeps the same hands-on design: the surgeon holds and guides the instrument directly, with no joystick or console. The robot compensates for hand tremor, prevents eye rotation about the scleral port, and can immobilize the instrument for prolonged periods with a hold function. In a prospective single-center series (June 2024–August 2025), 20 eyes with submacular hemorrhage underwent vitrectomy and subretinal injection of recombinant tPA through attached retina, using a 38G needle and microinjection system mounted on the robot. The robot held the needle tip in the subretinal space while the surgeon controlled the injection, with a mean injection duration of 178 ± 34 seconds and stable subretinal needle positioning maintained for at least 3 minutes in all eyes; there were no device-associated adverse events, the hemorrhage was completely displaced from the fovea in 95% of eyes, and median visual acuity improved from counting fingers to approximately 20/90 at 6 weeks, although postoperative vitreous hemorrhage (25%) and RPE tears (20%) were common. The overall takeaway was that robotic co-manipulation allows stable, low-pressure subretinal delivery through attached retina, a capability directly relevant to gene therapy.[52]
  • Luca robotic platform: Developed by the French start-up AcuSurgical, Luca is a bimanual telemanipulator with two independent robotic arms positioned on either side of the patient’s head, each holding a standard disposable vitreoretinal instrument, which the surgeon controls from an ergonomic piloting station with 3D visualization. The manufacturer reports precision of approximately 10 µm with tremor elimination, and unlike single-arm systems Luca is designed to perform complete vitreoretinal procedures, with a safety override that lets the surgeon immediately resume manual control. In a prospective, single-arm, first-in-human study conducted at Ghent University Hospital, Belgium, between February and June 2024, seven patients undergoing surgery for epiretinal membrane (n=6) or macular hole (n=1) were enrolled. The robot was used for posterior vitreous detachment induction and core vitrectomy, while the remaining surgical steps were completed manually. The planned robot-assisted portion was successfully completed in six of seven patients (85.7%), with no device-related adverse events or serious adverse events reported. No surgical steps were automated, as the robot reproduced the surgeon's movements. These early clinical findings support the feasibility and preliminary safety of bimanual robotic telemanipulation; however, larger comparative studies are necessary to establish its clinical advantages over conventional surgery.[29][53][54]
  • OQrimo, an intraocular endoscope-holding robot, was approved as a medical device in Japan in 2023 and has been reported in initial clinical use in eight eyes, where it maintained stable endoscope positioning and permitted peripheral retinal visualization without scleral indentation.[30][2]

Integration into Practice:

For ophthalmologists to successfully integrate RAVS into their surgical practice, three key considerations should be addressed:

Cost: Robotic systems like the PRECEYES Surgical System, da Vinci (adapted), or other microsurgical platforms require substantial capital investment, often ranging from hundreds of thousands to over a million USD, depending on the system and necessary modifications for ophthalmic use.[55] Ongoing maintenance contracts, software upgrades, and technician support can add significantly to the long-term cost. In addition, training surgical teams — both surgeons and scrub staff — involves additional time and financial resources. Currently, no dedicated reimbursement codes exist for RAVS procedures, which can make cost recovery more difficult for private practices and smaller centers. Hospitals may hesitate to invest without a clear financial return. Though upfront costs are high, potential long-term benefits — such as increased precision, fewer complications, shorter recovery times, and possibly reduced OR time — may offset the investment. However, this cost-benefit relationship is not yet well-documented in large-scale, peer-reviewed economic evaluations.

Operating Room Set-up Time: In other surgical disciplines, robotic procedures are well-documented to require longer setup times. One study reported that robotic surgery setup took, on average, over 20 minutes longer than manual surgical preparation. [56]While RAVS systems initially require longer operative times due to setup and the learning curve, recent advancements and increased surgeon experience have demonstrated that procedure durations can become comparable to those of manual surgery. [45] A prospective assessment of robot-assisted epiretinal membrane peeling found that preoperative and intraoperative times improved with accumulating experience, supporting this trend.[57]

Flattening the learning curve: There will be a substantial learning curve for the surgeon but also for the surgical assistant and team in the operating room. Standardized training modules for robotic ophthalmic trainees and surgical teams will allow for improved safety outcomes for patients electing for RAVS. [58]

Patient Selection

Indications

Robotic-assisted vitreoretinal surgery is primarily recommended for procedures that demand a level of precision and stability beyond the physiological limits of manual dexterity. This technology has shown feasibility and safety for several vitreoretinal interventions where micron-level accuracy is essential.[59][16]

Epiretinal Membrane (ERM) and Internal Limiting Membrane (ILM) Peeling: The removal of these extremely thin membranes from the retinal surface requires meticulous technique to avoid damaging the delicate underlying neural tissue. Robotic systems provide enhanced precision and control in these procedures.[59] In clinical trials using the Preceyes Surgical System, ERM peels were completed with high accuracy. [60] These cases were chosen as early evaluations of robotic systems because they are commonly performed yet technically challenging, serving as robust indicators for gauging robotic precision. [28] A comparative series of robot-assisted membrane peeling reported significantly fewer peeling grasps and fewer grasps per minute than manual peeling, with a reduction in intraoperative hemorrhages that did not reach statistical significance.[61]

Subretinal Injections: Precisely delivering therapeutic agents into the subretinal space is increasingly vital for emerging gene and cell therapies. Robotic platforms show promise in improving accuracy and control during these delicate injections. [59] As approved treatments like voretigene neparvovec-rzyl (Luxturna) gain traction for inherited retinal diseases, precise and minimally traumatic administration is critical to achieving optimal outcomes. [28] Robotic-assisted systems help maintain consistent cannula positioning and infusion rates, thereby minimizing reflux and accidental tissue damage. [59] In a model study comparing nine surgeons with and without robotic assistance, the robot reduced drift from a median of 212 to 16 micrometers and tremor from 18 to 1 micrometer, and permitted longer injection times with a higher rate of bleb formation.[5]This technology may also enable subretinal injections to be performed under intravenous sedation rather than general anesthesia, representing a potential shift in clinical workflow and patient safety considerations.[26]

Retinal Vein Cannulation (RVC): Addressing retinal vein occlusions via cannulation of the occluded vessel and direct delivery of thrombolytic drugs is extremely challenging due to the small diameter and fragility of retinal vessels. By stabilizing instruments and filtering out hand tremors, robotics can make these procedures more feasible. [62] The KU Leuven co-manipulator system accomplished the first robot-assisted RVC in humans, enabling stable injection of ocriplasmin for up to 10 minutes. [60]This procedure, which necessitates sustained needle placement in vessels measuring only 80-120 μm at the optic disc, exemplifies the potential of robotic systems for treatments previously considered unachievable.[28]

Submacular Hemorrhage Management: Research shows the successful application of robotic surgery for subretinal drug delivery in the management of submacular hemorrhage. [28] In such cases, the Preceyes system was used to administer recombinant tissue plasminogen activator (r-TPA) subretinally under local anesthesia in patients with hemorrhage secondary to age-related macular degeneration. Clinical trials noted fewer retinotomies and reduced retinal microtrauma when compared with manual techniques. [16]

Complex Micron-Scale Interventions: Certain advanced vitreoretinal procedures, including tractional retinal detachment repairs, require coordinated bimanual maneuvers at a microscopic level, pushing human dexterity to its limits. Robotic assistance may offer the stability and precision necessary for these intricate surgical tasks.[59] Comparative studies suggest reduced retinal microtrauma with robot-assisted methods, indicating potential safety benefits for delicate maneuvers near the macula. [28]

Core Vitrectomy and Posterior Vitreous Detachment: Bimanual telemanipulated core vitrectomy and induction of posterior vitreous detachment have now been shown to be feasible in patients, extending robotic assistance beyond focal macular tasks to a core step of the operation.[29]

Contraindications

Even though RAVS continues to broaden its scope, certain factors must be considered to determine optimal patient selection. Contraindications often relate to the patient-specific factors, current limitations of robotic technology, or surgeon-related considerations.

Patient-Related Factors: Some RAVS may take more time to complete compared to standard manual surgery, which can be a drawback in urgent cases where delay might lead to irreversible vision loss. [59] Though several robotic procedures can be done under local anesthesia, certain systems or complex interventions might require general anesthesia with neuromuscular blockade to ensure patient stillness—an important consideration for those with higher anesthesia-related risks. [63]

Patients with pronounced involuntary eye movements or difficulty maintaining a steady gaze may also be unsuitable for robotic surgery, as these issues could undermine the precision of robotic instrument manipulation. [60] In addition, specific anatomical characteristics that limit robotic instrument access may serve as relative contraindications.

Limitations of Current Robotic Technology: One notable drawback of many robotic systems is the lack of tactile or force feedback, which is particularly important in delicate intraocular environments. [59] Surgeons often rely on subtle tactile cues to prevent tissue damage, especially as the forces involved can fall below the threshold of human tactile perception. [62] Furthermore, the bulk of some robotic devices and the limited availability of specialized ophthalmic instruments designed for robotic use can restrict certain applications. [64]However, recent systems are incorporating advancing sensing technologies, including instrument-integrated OCT and experimental haptic interfaces, to improve feedback and reduce reliance on visual cues alone.[7][65]

Additional technical hurdles include potential sensor-actuation lag, high computational demands for real-time intraoperative OCT, and alignment discrepancies between the robotic mechanism and the patient’s eye—all of which may influence safety and efficacy in specific scenarios. [66] Moreover, the cost and maintenance associated with these systems, along with limited accessibility at many centers, remain practical barriers that can limit widespread adoption. [60]

Surgeon-Related Factors: Safe and effective use of robotic platforms requires specialized training and experience. The learning curve can limit the immediate availability of surgeons proficient in this technology, consequently restricting patient access. [62] In instances where a surgeon already has extensive proficiency in manual vitreoretinal techniques with excellent outcomes, the perceived advantages of switching to robotics may not outweigh the time and effort needed to adapt. [60]

Surgical Technique

Preoperative Planning and Setup: A comprehensive preoperative assessment, including detailed fundus evaluation and OCT imaging, is essential to plan the surgical approach and define the target area. [67] After preparing the patient and administering appropriate anesthesia, the robotic system (e.g., Preceyes) is positioned—often at the temporal side of the operating table—and meticulously draped. [28]

The patient’s head is stabilized using a specialized headrest to maintain consistent eye orientation, critical for ensuring precision during robotic manipulation. [57]Access ports for robotic instruments and illumination are created using standard small-gauge vitreoretinal trocars (commonly 23–27 gauge). For the Preceyes system, a conical-shaped scleral port adaptor secures the manipulator to the eye, maintaining a steady platform for intraocular maneuvers. [28]

Robotic Systems and Control Mechanisms: Various robotic systems exist, each with unique design features. The Preceyes Surgical System (CE-marked) employs a telemanipulator strategy where the surgeon controls a motion controller, which drives a robotic arm to achieve tool-tip accuracy of around 10 μm. [28]

During surgery, the surgeon manipulates the robotic arm via intuitive hand controls. Many setups include motion scaling, converting larger hand movements into fine, precise movements at the instrument tip. [68] These systems can also dampen physiological tremors (typically 8–12 Hz), significantly improving stability during delicate tasks. [62]

Preceyes allows the surgeon to maneuver in four axes using a hand-motion controller, translating broad-scale surgeon inputs into precise movements within the eye. [28] Some platforms incorporate virtual boundaries to prevent instruments from exceeding predefined limits in the ocular space, and many offer a “hold” or “freeze” feature that stabilizes the instrument tip during particularly delicate phases. [68]

Surgical Procedures and Techniques: In membrane peeling (ERM or ILM), a conventional pars plana vitrectomy is first performed. The robotic component then controls a fine needle or pick to initiate a flap on the membrane away from the macular surface, guided by intraoperative OCT. [28] Although robotic procedures generally take longer, clinical outcomes have been equivalent or superior to manual surgery, with decreased rates of microtrauma or minor bleeding. [28]

For subretinal injections, the Preceyes system has facilitated subretinal administration of recombinant tissue plasminogen activator (r-TPA) under local anesthesia in patients presenting with submacular hemorrhage. Following vitrectomy, a 41G cannula is advanced toward the hemorrhagic area under z-axis control, connected to a foot-controlled fluid system for steady injection under real-time OCT visualization. [28] Fewer retinotomies and less retinal damage have been reported when compared to conventional techniques. [16]

In RVC, initial studies using the Preceyes system in animal models have shown successful vein entry and maintenance of the cannula for up to 20 minutes. [28] The KU Leuven co-manipulator system accomplished the first human RVC by stabilizing a needle tip in the vein to deliver ocriplasmin for 10-minute intervals. [60]

Integration with Imaging Technologies: The incorporation of intraoperative OCT in robotic surgery marks a significant advancement, providing high-resolution, real-time cross-sectional images of the surgical field. This allows for precise visualization of instrument-to-tissue interactions. [69] For the Preceyes system, real-time OCT helps confirm accurate retinotomy creation, facilitates subretinal injections, and monitors bleb formation. [28]

Current advances extend these capabilities through instrument-integrated OCT, which uses distance measurements from the surgical instrument to generate an adaptive intraoperative model of the eye, facilitating more accurate virtual boundary placement. Curvature-corrected registration further enables alignment of preoperative diagnostic OCT with the intraoperative view. [1,2] More advanced systems incorporate dual-channel OCT (A-scan and C-scan) to provide simultaneous real-time depth and spatial visualization, improving instrument tracking and visualization of instrument–tissue interactions while enabling continuous retinal monitoring during surgery.[70][71] [72] Additionally, integration of advanced imaging modalities such as intraoperative OCT may initially increase cognitive load, though it has been associated with improved depth perception and surgical precision over time.[73]

Outcomes

Robotic-assisted vitreoretinal surgery (RAVS) has shown promising outcomes in terms of precision and safety, although it generally requires more time compared to manual surgery. Here, are some of the measured outcomes that have been explored in RAVS.

Surgical Success: Current evidence is mixed regarding whether RAVS yields outcomes equivalent to or better than those of manual surgical techniques. A randomized controlled trial found that both experienced and novice vitreoretinal surgeons achieved greater precision using robotic-assisted techniques compared to manual surgery, although the reduction in tissue damage reached statistical significance only in the novice group.[74]More recent studies further demonstrate improved procedural success in specific applications, particularly subretinal injections, where robotic assistance enhances consistency and control, though without clear superiority in overall clinical outcomes.[7][54]

  • Compensation for physiologic tremor: A physiological hand tremor with a root-mean-square vector magnitude of 156 micrometers is inherent to vitreoretinal surgeons. Robotic surgical technologies aim to identify and counteract this tremor in real time.[75][76] The same measurements gave root-mean-square amplitudes of 76 to 101 micrometers in the individual spatial axes during a stationary pointing task.[75]
  • Prevention of Eye Rotation:  One significant advantage of RAVS is the implementation of adaptive force control methods, which actively counteract any excessive forces applied to the sclera, thereby stabilizing the eye and preventing unintended 38movements.[77]
  • Increased ability for tool immobilization: Systems like the Steady-Hand Eye Robot (SHER) employ optimized tilt mechanisms and adaptive force control strategies to maintain tool stability. They actively mitigate excessive forces applied to the sclera, ensuring precise tool placement and minimizing the risk of tissue damage.[78]
  • Enhanced procedural consistency: Robotic assistance may improve the reproducibility of fine microsurgical tasks, particularly in applications such as subretinal injections and retinal vein cannulation, where sustained precision is required.[7] [8]

Longer Operative Time:  The first human study of remotely controlled robot-assisted retinal surgery performed through a telemanipulation device was done on 12 patients. Each group—manual surgery and RAVS—included six patients. Overall, the dissection time was significantly longer in the RAVS group (4 mins 5 seconds median time) when compared to the manual surgery group (1 min 20 seconds). This comparison refers to the dissection step specifically rather than to total operative time, and surgical success and retinal microtrauma did not differ significantly between the groups.[3] Prolonged operative time, however, may elevate the risk of intraoperative and postoperative complications.

Learning Curve and Training Considerations: Successful implementation of RAVS hinges on targeted training programs. Familiarity with the Preceyes system, for example, is often gained through simulations and team-based sessions with surgeons, assistants, and operating room staff. [28] Comparative studies reveal that while the learning trajectories for robot-assisted and manual surgery may be similar, robot-assisted approaches can reduce overall instrument movement and tissue stress—benefits that are particularly relevant for less experienced surgeons.[74] Evaluation of shared and full autonomy in a realistic eye model has shown that a one-hand teleoperation mode improved expert positioning accuracy and shortened the novice learning curve, and that autonomous positioning achieved accuracy equivalent to that of surgeons in a constrained task.[79]

Telesurgery: Robot-assisted subretinal injection of recombinant tissue plasminogen activator for submacular hemorrhage has been performed by a surgeon approximately 4000 kilometers from the patient, with 7 minutes of robotic teleoperation within a 46-minute operation and a mean network latency of 77.9 milliseconds. The hemorrhage resolved completely by postoperative day 26 with no serious adverse events over 3 months. This is a single case and establishes proof of concept only, but it suggests a route to expanding access to specialized retinal procedures in geographically remote regions.[80]

Maturity of the Evidence Base: A 2026 bibliometric analysis of the field identified 129 indexed records published between 2008 and 2026, of which 98 original articles contained substantive empirical evaluation. Of these, 53 were technical or simulation studies and 35 were preclinical, leaving only 10 human clinical studies. Publication growth has therefore outpaced the accumulation of human clinical evidence.[81]

Complications

Common complications associated with vitreoretinal surgery include cataract formation, retinal breaks, retinal detachments, endophthalmitis, and macular hole formation. For example, endophthalmitis is rare, occurring in less than 0.05% of vitrectomies. Macular hole formation is also a potential complication, particularly in surgeries for epiretinal membrane and vitreomacular traction.[82] The complication rates of RAVS and manual surgery are comparable in both incidence and types of complications, with neither approach linked to a higher risk of adverse outcomes.[74] [16]

Equipment Failure: As with all robotic systems, there exists a risk of equipment malfunction or failure, potentially causing intraoperative delays or requiring conversion to manual surgery.[83]

Instrument Failure During Cannulation: In the phase I retinal vein cannulation trial, a microneedle tip fractured in one of four eyes and was removed with endoforceps, with no other intervention-related complications reported.[50]

Reduced Sensory Feedback: Surgeons may have limited tactile feedback, which could impair their ability to assess the force applied during delicate maneuvers, thereby potentially raising the risk of iatrogenic injury.[77]

Conclusion

Robotic-assisted vitreoretinal surgery (RAVS) represents a groundbreaking advancement in ophthalmic microsurgery, offering enhanced precision, stability, and control beyond the limits of the human hand. While still in its early stages, RAVS has demonstrated promising outcomes in complex tasks such as subretinal injections and membrane peeling. However, widespread adoption will depend on addressing key challenges, including high initial costs, integration into surgical workflows, and the need for specialized training. As technology evolves and evidence accumulates, RAVS has the potential to redefine the future of vitreoretinal surgery. On present evidence, RAVS is best understood as a selective precision platform for high-demand retinal interventions rather than a replacement for manual surgery, and multicenter validation, standardized safety and surgical endpoints, training frameworks, cost-effectiveness analysis, and clearer regulatory pathways remain the priorities for translation.[81][16]

References

  1. ↑ Nasseri MA, et al. Robotic vitreoretinal surgery: current perspectives. Robot Surg. 2019;3:11–20.
  2. ↑ 2.0 2.1 2.2 Nakao S, Tadano K, Sonoda KH. Advancements in robotic surgery for vitreoretinal diseases: current trends and the future. Jpn J Ophthalmol. 2025;69(4):483-494. doi:10.1007/s10384-025-01231-1
  3. ↑ 3.0 3.1 Edwards TL, et al. First-in-human study of the safety and viability of using the Preceyes surgical system for microinjection into the retina. Nat Biomed Eng. 2018;2(9):649–656.
  4. ↑ 4.0 4.1 4.2 Forslund Jacobsen M, Konge L, Alberti M, la Cour M, Park YS, Thomsen ASS. Robot-assisted vitreoretinal surgery improves surgical accuracy compared with manual surgery: a randomized trial in a simulated setting. Retina. 2020;40(11):2091-2098. doi:10.1097/IAE.0000000000002720
  5. ↑ 5.0 5.1 5.2 Ladha R, Meenink T, Smit J, de Smet MD. Advantages of robotic assistance over a manual approach in simulated subretinal injections and its relevance for gene therapy. Gene Ther. 2021;30(3-4):264-270. doi:10.1038/s41434-021-00262-w
  6. ↑ Gonenc B, Handa J, Gehlbach P, Taylor RH, Iordachita I. Design of 3-DOF force sensing micro-forceps for robot assisted vitreoretinal surgery. Conf Proc IEEE Eng Med Biol Soc. 2013;2013:5686–5689.
  7. ↑ 7.0 7.1 7.2 7.3 Poh SSJ, Sia JT, Yip MYT, et al. Artificial Intelligence, Digital Imaging, and Robotics Technologies for Surgical Vitreoretinal Diseases. Ophthalmol Retina. 2024;8(7):633-645. doi:10.1016/j.oret.2024.01.018
  8. ↑ 8.0 8.1 8.2 Lian Z, Xu A, Li Y, et al. Robotic augmentation of surgical skills in subretinal injection: a novel semiautomated system. Int J Surg. Published online December 16, 2025. doi:10.1097/JS9.0000000000004501
  9. ↑ Turgut F, Somfai GM, Heussen FM, Eberle A, de Smet MD, Becker MD. Robot-Assisted Epiretinal Membrane Peeling: A Prospective Assessment of Pre- and Intra-Operative Times and of Surgeons' Subjective Perceptions. J Clin Med. 2023;12(8):2768. Published 2023 Apr 7. doi:10.3390/jcm12082768
  10. ↑ Eberle A, Turgut F, Somfai GM, et al. Comparison of Surgical Times Between Manual and Robot-Assisted Epiretinal Membrane Peeling. Transl Vis Sci Technol. 2024;13(8):27. doi:10.1167/tvst.13.8.27
  11. ↑ Taylor RH, et al. An overview of medical robotics. IEEE Trans Robot Autom. 1999.
  12. ↑ 12.0 12.1 Rahimy E, Wilson J, Tsao TC, Schwartz SD. Robot-assisted intraocular surgery: development of the IRISS and feasibility studies in an animal model. Retina. 2013;33(7):1350–1356.
  13. ↑ Schütz L, Dehghani S, Sommersperger M, Faridpooya K, Navab N. The impact of intraoperative optical coherence tomography on cognitive load in virtual reality vitreoretinal surgery training. Sci Rep. 2025;15(1):24848. Published 2025 Jul 10. doi:10.1038/s41598-025-07670-7
  14. ↑ He X, Balicki M, Gehlbach P, Handa J, Taylor R, Iordachita I. A multi-function force sensing instrument for variable admittance robot control in retinal microsurgery. IEEE Int Conf Robot Autom. 2014;2014:1411-1418. doi:10.1109/ICRA.2014.6907037
  15. ↑ Patel N, Urias M, Ebrahimi A, Taylor RH, Gehlbach P, Iordachita I. Force-based control for safe robot-assisted retinal interventions: evaluation in animal studies. IEEE Trans Med Robot Bionics. 2022;4(3):578-587. doi:10.1109/tmrb.2022.3191441
  16. ↑ 16.0 16.1 16.2 16.3 16.4 16.5 Thirunavukarasu AJ, Hu ML, Foster WP, Xue K, Cehajic-Kapetanovic J, MacLaren RE. Robot-Assisted Eye Surgery: A Systematic Review of Effectiveness, Safety, and Practicality in Clinical Settings. Transl Vis Sci Technol. 2024;13(6):20. doi:10.1167/tvst.13.6.20
  17. ↑ Machemer R, Parel J-M, Buettner H. A new concept for vitreous surgery: 1. Instrumentation. American journal of ophthalmology. 1972;73(1):1–7. doi: 10.1016/0002-9394(72)90295-4
  18. ↑ Spitznas M. Motorized teleguided stereotactic micromanipulator for vitreous microsurgery. Archives of ophthalmology (Chicago, Ill: 1960) 1983;101(4):623–630. doi: 10.1001/archopht.1983.01040010623020.
  19. ↑ Guerrouad A, Vidal P. SMOS: stereotaxical microtelemanipulator for ocular surgery. Paper presented at: Engineering in Medicine and Biology Society, 1989. Images of the Twenty-First Century., Proceedings of the Annual International Conference of the IEEE Engineering in 1989; 9–12 Nov, 1989; Seattle, WA, USA.
  20. ↑ Kwoh YS, Hou J, Jonckheere EA, Hayati S. A robot with improved absolute positioning accuracy for CT guided stereotactic brain surgery. IEEE transactions on biomedical engineering. 1988;35(2):153–160. doi: 10.1109/10.1354.
  21. ↑ Paul HA, Bargar WL, Mittlestadt B, et al. Development of a surgical robot for cementless total hip arthroplasty. Clinical orthopaedics and related research. 1992;(285):57–66
  22. ↑ Tsirbas A, Mango C, Dutson E. Robotic ocular surgery. British Journal of Ophthalmology. 2007;91:18–21
  23. ↑ Douglas R. Robotic surgery in ophthalmology: reality or fantasy? British Journal of Ophthalmology. 2007;91:1–1.
  24. ↑ Channa R, Iordachita I, Handa JT. Robotic vitreoretinal surgery. Retina. 2017;37(7):1220-1228. doi:10.1097/IAE.0000000000001398
  25. ↑ Nicholas R. Posselli et al. Head-mounted surgical robots are an enabling technology for subretinal injections.Sci. Robot.10,eadp7700(2025).DOI:10.1126/scirobotics.adp7700
  26. ↑ 26.0 26.1 https://attheu.utah.edu/science-technology/early-study-shows-promise-for-retinal-surgery-robot-invented-at-the-university-of-utah/
  27. ↑ https://retinatoday.com/articles/2025-nov-dec/robotics-in-retinal-surgery-recent-advances-and-applications
  28. ↑ 28.00 28.01 28.02 28.03 28.04 28.05 28.06 28.07 28.08 28.09 28.10 28.11 28.12 28.13 28.14 28.15 28.16 Mi H, MacLaren RE, Cehajic-Kapetanovic J. Robotising vitreoretinal surgeries. Eye (Lond). 2025 Mar;39(4):673-682. doi: 10.1038/s41433-024-03149-3. Epub 2024 Jul 4. PMID: 38965320; PMCID: PMC11885832.
  29. ↑ 29.0 29.1 29.2 Nerinckx F, Van Slycken M, Van Puyvelde J, Leroy B. Telemanipulated robot-assisted vitreoretinal surgery: safety and effectiveness of the Luca system in robotically performed core vitrectomy in ERM or macular hole surgical treatment. Retina. 2026. doi:10.1097/IAE.0000000000004958
  30. ↑ 30.0 30.1 Kiyohara K, Ishikawa K, Yuge K, Yamana S, Nakao S, Sonoda KH. Initial clinical use of the intraocular endoscope holding robot in pars plana vitrectomy. Jpn J Ophthalmol. 2026;70(2):358-366. doi:10.1007/s10384-025-01285-1
  31. ↑ 31.0 31.1 de Smet MD, Meenink TCM, Janssens T, Vanheukelom V, Naus GJL, Beelen MJ, et al. Robotic Assisted Cannulation of Occluded Retinal Veins. PLoS One. 2016;11:e0162037.
  32. ↑ MacLachlan RA, Becker BC, Tabares JC, Podnar GW, Lobes LA, Riviere CN. Micron: An Actively Stabilized Handheld Tool for Microsurgery. IEEE Transactions on Robotics. 2012;28:195–212.
  33. ↑ Gonenc B, Chae J, Gehlbach P, Taylor RH, Iordachita I. Towards Robot-Assisted Retinal Vein Cannulation: A Motorized Force-Sensing Microneedle Integrated with a Handheld Micromanipulator †. Sensors (Basel).
  34. ↑ He X, Roppenecker D, Gierlach D, Balicki M, Olds K, Gehlbach P, et al. Toward Clinically Applicable Steady-Hand Eye Robot for Vitreoretinal Surgery. In: Volume 2: Biomedical and Biotechnology. American Society of Mechanical Engineers; 2012;145–53.
  35. ↑ Taylor R, Jensen P, Whitcomb L, Barnes A, Kumar R, Stoianovici D, et al. A Steady-Hand Robotic System for Microsurgical Augmentation. In 1999;1031–41.
  36. ↑ Wilson JT, Gerber MJ, Prince SW, Chen CW, Schwartz SD, Hubschman JP, et al. Intraocular robotic interventional surgical system (IRISS): Mechanical design, evaluation, and master-slave manipulation. Int J Med Robot. 2018;14.
  37. ↑ Wilson JT, Tsao TC, Hubschman JP, Schwartz S. Evaluating remote centers of motion for minimally invasive surgical robots by computer vision. In: 2010 IEEE/ASME International Conference on Advanced Intelligent Mechatronics. IEEE; 2010;1413–8
  38. ↑ Wang H, Foroutani Y, Nepo M, Rodriguez M, Ma J, Hubschman JP, Tsao TC, Rosen J. Control modes of teleoperated surgical robotic system's tools in ophthalmic surgery. IEEE Trans Med Robot Bionics. 2025;7(4):1455-1464. doi:10.1109/tmrb.2025.3604102
  39. ↑ Nasseri MA, Eder M, Nair S, Dean EC, Maier M, Zapp D, et al. The introduction of a new robot for assistance in ophthalmic surgery. Annu Int Conf IEEE Eng Med Biol Soc. 2013;2013:5682–5
  40. ↑ Iordachita II, de Smet MD, Naus G, Mitsuishi M, Riviere CN. Robotic Assistance for Intraocular Microsurgery: Challenges and Perspectives. Proc IEEE Inst Electr Electron Eng. 2022;110:893–908.
  41. ↑ Zhou M, Roodaki H, Eslami A, Chen G, Huang K, Maier M, et al. Needle Segmentation in Volumetric Optical Coherence Tomography Images for Ophthalmic Microsurgery. Applied Sciences. 2017;7:748.
  42. ↑ Charreyron SL, Zeydan B, Nelson BJ. Shared control of a magnetic microcatheter for vitreoretinal targeted drug delivery. In: 2017 IEEE International Conference on Robotics and Automation (ICRA). IEEE; 2017;4843–8
  43. ↑ Charreyron SL, Boehler Q, Danun AN, Mesot A, Becker M, Nelson BJ. A Magnetically Navigated Microcannula for Subretinal Injections. IEEE Trans Biomed Eng. 2021;68:119–29.
  44. ↑ Maberley DAL, Beelen M, Smit J, Meenink T, Naus G, Wagner C, et al. A comparison of robotic and manual surgery for internal limiting membrane peeling. Graefes Arch Clin Exp Ophthalmol. 2020;258:773–8.
  45. ↑ 45.0 45.1 Cehajic-Kapetanovic J, Xue K, Edwards TL, Meenink TC, Beelen MJ, Naus GJ, et al. First-in-Human Robot-Assisted Subretinal Drug Delivery Under Local Anesthesia. Am J Ophthalmol. 2022;237:104–13
  46. ↑ Edwards, T.L., Xue, K., Meenink, H.C.M. et al. First-in-human study of the safety and viability of intraocular robotic surgery. Nat Biomed Eng 2, 649–656 (2018). https://doi.org/10.1038/s41551-018-0248-4
  47. ↑ Cehajic-Kapetanovic J, Xue K, Edwards TL, et al. First-in-Human Robot-Assisted Subretinal Drug Delivery Under Local Anesthesia. Am J Ophthalmol. 2022;237:104-113. doi:10.1016/j.ajo.2021.11.011
  48. ↑ Gijbels A, Smits J, Schoevaerdts L, Willekens K, Vander Poorten EB, Stalmans P, et al. In-Human Robot-Assisted Retinal Vein Cannulation, A World First. Ann Biomed Eng. 2018;46:1676–85
  49. ↑ Willekens K, Gijbels A, Schoevaerdts L, Esteveny L, Janssens T, Jonckx B, et al. Robot-assisted retinal vein cannulation in an in vivo porcine retinal vein occlusion model. Acta Ophthalmol. 2017;95:270–5.
  50. ↑ 50.0 50.1 Willekens K, Gijbels A, Smits J, Schoevaerdts L, Blanckaert J, Feyen JHM, Reynaerts D, Stalmans P. Phase I trial on robot assisted retinal vein cannulation with ocriplasmin infusion for central retinal vein occlusion. Acta Ophthalmol. 2021;99(1):90-96. doi:10.1111/aos.14480
  51. ↑ Gijbels, A., Smits, J., Schoevaerdts, L. et al. In-Human Robot-Assisted Retinal Vein Cannulation, A World First. Ann Biomed Eng 46, 1676–1685 (2018). https://doi.org/10.1007/s10439-018-2053-3
  52. ↑ De Clerck I, Schoovaerts M, Polidoro M, Ourak M, Vander Poorten E, Stalmans P. IN-HUMAN FEASIBILITY AND SAFETY OF SUBRETINAL DRUG INJECTION THROUGH ATTACHED RETINA USING A ROBOTIC COMANIPULATION SYSTEM. Retina. 2026;46(5):811-818. doi:10.1097/IAE.0000000000004745
  53. ↑ https://www.surgicalroboticstechnology.com/news/acusurgical-completes-first-clinical-study-with-luca-robotic-surgery-platform/
  54. ↑ 54.0 54.1 https://www.retinalphysician.com/issues/2025/julyaugust/robotic-system-tested-in-retinal-surgery/
  55. ↑ Perez, Rafael E., and Steven D. Schwaitzberg. “Robotic Surgery: Finding Value in 2019 and Beyond.” Annals of Laparoscopic and Endoscopic Surgery, AME Publishing Company, 30 May 2019, ales.amegroups.org/article/view/5205.
  56. ↑ Iranmanesh P, Morel P, Wagner OJ, Inan I, Pugin F, Hagen ME. Set-up and docking of the da Vinci ® surgical system: prospective analysis of initial experience. The International Journal of Medical Robotics and Computer Assisted Surgery. 2010;6:57–60.
  57. ↑ 57.0 57.1 Turgut F, Somfai GM, Heussen FM, Eberle A, de Smet MD, Becker MD. Robot-Assisted Epiretinal Membrane Peeling: A Prospective Assessment of Pre- and Intra-Operative Times and of Surgeons’ Subjective Perceptions. Journal of Clinical Medicine. 2023;12(8):2768. doi:10.3390/jcm12082768
  58. ↑ He B, de Smet MD, Sodhi M, Etminan M, Maberley D. A review of robotic surgical training: establishing a curriculum and credentialing process in ophthalmology. Eye (Lond). 2021;35:3192–201.
  59. ↑ 59.0 59.1 59.2 59.3 59.4 59.5 59.6 Fridami Dewi AA, Jutamulia J, Anggi Paramitha DA. A Systematic Review of Robot-assisted vs Manual Vitreoretinal Surgery: Is it Feasible? Int J Res Rev. 2023;10(10):1-9. doi:10.52403/ijrr.20231001
  60. ↑ 60.0 60.1 60.2 60.3 60.4 60.5 Ramamurthy SR, and Dave VP. Robotics in Vitreo-Retinal Surgery. Seminars in Ophthalmology. 2022;37(7-8):795-800. doi:10.1080/08820538.2022.2075705
  61. ↑ Eberle A, Turgut F, Somfai GM, Saad A, de Smet MD, Hasler PW, Heussen FM, Becker MD. Comparison of surgical times between manual and robot-assisted epiretinal membrane peeling. Transl Vis Sci Technol. 2024;13(8):27. doi:10.1167/tvst.13.8.27
  62. ↑ 62.0 62.1 62.2 62.3 Roizenblatt M, Edwards T, Gehlbach PL. Robot-assisted vitreoretinal surgery: current perspectives. RSRR. 2018;Volume 5:1-11. doi:10.2147/RSRR.S122301
  63. ↑ Nuzzi R, Brusasco L. State of the art of robotic surgery related to vision: brain and eye applications of newly available devices. EB. 2018;10:13-24. doi:10.2147/EB.S148644
  64. ↑ Ahronovich EZ, Simaan N, Joos KM. A Review of Robotic and OCT-Aided Systems for Vitreoretinal Surgery. Adv Ther. 2021;38(5):2114-2129. doi:10.1007/s12325-021-01692-z
  65. ↑ Cereda MG, Parrulli S, Douven YGM, et al. Clinical Evaluation of an Instrument-Integrated OCT-Based Distance Sensor for Robotic Vitreoretinal Surgery. Ophthalmol Sci. 2021;1(4):100085. Published 2021 Nov 26. doi:10.1016/j.xops.2021.100085
  66. ↑ Gerber MJ, Pettenkofer M, Hubschman JP. Advanced robotic surgical systems in ophthalmology. Eye. 2020;34(9):1554-1562. doi:10.1038/s41433-020-0837-9
  67. ↑ Inagaki S, Alikhani A, Navab N, Issa PC, Nasseri MA. Pre-Surgical Planner for Robot-Assisted Vitreoretinal Surgery: Integrating Eye Posture, Robot Position and Insertion Point. [Preprint, not peer reviewed.] Published online February 25, 2025. doi:10.48550/arXiv.2502.18230
  68. ↑ 68.0 68.1 Wang T, Xia J, Jin L, et al. Comparison of robot-assisted vitreoretinal surgery and manual surgery in different preclinical settings: a randomized trial. Annals of Translational Medicine. 2022;10(21):1163-1163. doi:10.21037/atm-22-1315
  69. ↑ Molaei A, Abedloo E, De Smet M, et al. Toward the Art of Robotic‑assisted Vitreoretinal Surgery. Journal of Ophthalmic & Vision Research. 2017;12:212-218. doi:10.4103/jovr.jovr_63_17
  70. ↑ Briel M, Haide L, Hess M, Schimmelpfennig J, Matten P, Peter R, Hillenbrand M, Tagliabue E, Mathis-Ullrich F. Intraoperative adaptive eye model based on instrument-integrated OCT for robot-assisted vitreoretinal surgery. Int J Comput Assist Radiol Surg. 2025;20(5):881-889. doi:10.1007/s11548-025-03325-0
  71. ↑ Briel M, Haide L, Meyling M, Saalfrank B, Matten P, Piccinelli N, Kronreif G, Spadea MF, Tagliabue E, Mathis-Ullrich F. Curvature-corrected retinal registration of diagnostic OCT with instrument-integrated OCT. Sci Rep. 2025;15(1):42933. doi:10.1038/s41598-025-28922-6
  72. ↑ Xie Y, Huang Y, Bian GB, et al. Simultaneous OCT A-scan depth ranging and C-scan volume imaging for intraoperative robotic retinal surgery guidance. Biomed Opt Express. 2025;16(12):5078-5095. Published 2025 Nov 11. doi:10.1364/BOE.581579
  73. ↑ Schütz L, Dehghani S, Sommersperger M, Faridpooya K, Navab N. The impact of intraoperative optical coherence tomography on cognitive load in virtual reality vitreoretinal surgery training. Sci Rep. 2025;15(1):24848. Published 2025 Jul 10. doi:10.1038/s41598-025-07670-7
  74. ↑ 74.0 74.1 74.2 Forslund Jacobsen M, Konge L, Alberti M, la Cour M, Park YS, Thomsen ASS. ROBOT-ASSISTED VITREORETINAL SURGERY IMPROVES SURGICAL ACCURACY COMPARED WITH MANUAL SURGERY: A Randomized Trial in a Simulated Setting. Retina. 2020;40(11):2091-2098. doi:10.1097/IAE.0000000000002720
  75. ↑ 75.0 75.1 Peral-Gutierrez F, Liao AL, Riviere CN, editors. Engineering in Medicine and Biology Society, 2004 IEMBS'04 26th Annual International Conference of the IEEE. IEEE; 2004. Static and dynamic accuracy of vitreoretinal surgeons.
  76. ↑ S. Tatinati, K. Nazarpour, W. T. Ang and K. C. Veluvolu, "Multidimensional Modeling of Physiological Tremor for Active Compensation in Handheld Surgical Robotics," in IEEE Transactions on Industrial Electronics, vol. 64, no. 2, pp. 1645-1655, Feb. 2017, doi: 10.1109/TIE.2016.2597119. keywords: {Delays;Computational modeling;Instruments;Three-dimensional displays;Adaptation models;Robots;Solid modeling;Extreme learning machines (ELMs);handheld robotics;multidimensional modeling;physiological tremor},
  77. ↑ 77.0 77.1 Ebrahimi A, Alambeigi F, Zimmer-Galler IE, Gehlbach P, Taylor RH, Iordachita I. Toward Improving Patient Safety and Surgeon Comfort in a Synergic Robot-Assisted Eye Surgery: A Comparative Study. Rep U S. 2019;2019:7075-7082. doi:10.1109/IROS40897.2019.8967806
  78. ↑ Wu J, Li G, Urias M, et al. An Optimized Tilt Mechanism for a New Steady-Hand Eye Robot. Rep U S. 2020;2020:3105-3111. doi:10.1109/iros45743.2020.9340741
  79. ↑ Marinho MM, Koyama Y, Taniguchi Y, et al. Evaluation of (shared) autonomy in robot-assisted vitreoretinal surgery using a surgical model. Int J Med Robot. 2025;21(1):e70040. doi:10.1002/rcs.70040
  80. ↑ Xu A, Yang B, Liu B, Lu L, Lian Z, Chen W, Song R, Guo W, Alimu S, Liu Z, Liu D, Li Y, Xiao W, Nasseri MA, Huang K, Lin H. Ultra-long-distance robotic-assisted subretinal injection for submacular hemorrhage. JAMA Ophthalmol. 2026. doi:10.1001/jamaophthalmol.2026.3303
  81. ↑ 81.0 81.1 Wang J, Duan H, Liang L. Global research trends in robot-assisted vitreoretinal surgery: a visualized bibliometric analysis. J Robot Surg. 2026;20(1). doi:10.1007/s11701-026-03770-2
  82. ↑ Flaxel CJ, Adelman RA, Bailey ST, et al. Idiopathic Epiretinal Membrane and Vitreomacular Traction Preferred Practice Pattern® [published correction appears in Ophthalmology. 2020 Sep;127(9):1280. doi: 10.1016/j.ophtha.2020.06.045.]. Ophthalmology. 2020;127(2):P145-P183. doi:10.1016/j.ophtha.2019.09.022
  83. ↑ Jara RD, Guerrón AD, Portenier D. Complications of Robotic Surgery. Surg Clin North Am. 2020;100(2):461-468. doi:10.1016/j.suc.2019.12.008